| Literature DB >> 31788986 |
Wen Deng1,2, Junhua Li3, Xiaoqiang Liu1,2, Luyao Chen1, Weipeng Liu1, Xiaochen Zhou1, Jingyu Zhu3, Bin Fu1,2, Gongxian Wang1,2.
Abstract
OBJECTIVES: To present the perioperative, functional, and oncological outcomes of robot-assisted partial nephrectomy (RPN) compared with laparoscopic partial nephrectomy (LPN) for anatomically complex T1b renal tumors with RENAL nephrometry scores ≥7. PATIENTS AND METHODS: One hundred and seventy patients, during the study period, were retrospectively reviewed in our analysis according to inclusion criteria. Propensity score matching (PSM) (1:1) method was applied to impose restrictions on the potential baseline confounders. The comparisons of perioperative and functional outcomes between the RPN and LPN groups were conducted and analyzed after PSM, Kaplan-Meier analyses were performed to assess the differences about oncological outcomes between the two groups before and after PSM.Entities:
Keywords: T1b; laparoscopy; partial nephrectomy; renal tumor; robotics
Year: 2019 PMID: 31788986 PMCID: PMC6970028 DOI: 10.1002/cam4.2749
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
Preoperative characteristics by surgery type before and after propensity score matching
| Variable | Before propensity score matching | After propensity score matching | ||||
|---|---|---|---|---|---|---|
| LPN (n = 109) | RPN (n = 61) |
| LPN (n = 58) | RPN (n = 58) |
| |
| Age, y, mean (SD) | 50.6 (9.5) | 52.8 (10.3) | .168 | 50.6 (9.8) | 52.0 (10.0) | .449 |
| Gender (male), n (%) | 63 (57.8) | 31 (50.8) | .380 | 32 (55.2) | 31 (53.4) | .852 |
| Diabetes mellitus (yes), n (%) | 13 (11.9) | 7 (11.5) | .930 | 6 (10.3) | 7 (12.1) | .769 |
| Hypertension (yes), n (%) | 32 (29.4) | 13 (21.3) | .254 | 14 (24.1) | 13 (22.4) | .826 |
| ASA score (≥3), n (%) | 9 (8.3) | 6 (9.8) | .728 | 3 (5.2) | 6 (10.3) | .298 |
| RENAL score, median (IQR) | 8 (7‐9) | 8 (7‐9) | .535 | 8 (7‐9) | 8 (7‐9) | .635 |
| Left tumor, n (%) | 49 (45.0) | 32 (52.5) | .347 | 29 (50.0) | 32 (55.2) | .577 |
| Solitary kidney, n (%) | 14 (12.8) | 2 (3.3) |
| 3 (5.2) | 2 (3.4) | .648 |
| Hilar tumor, n (%) | 21 (19.3) | 16 (26.2) | .291 | 12 (20.7) | 15 (25.9) | .510 |
| Mean tumor size (cm), mean (SD) | 4.9 (0.7) | 5.0 (0.7) | .475 | 4.9 (0.7) | 5.0 (0.7) | .327 |
| Preoperative creatinine, umol/L, mean (SD) | 90.1 (25.3) | 87.1 (19.4) | .428 | 85.9 (24.5) | 87.0 (19.6) | .788 |
| Preoperative eGFR, mL/min, mean (SD) | 84.2 (18.7) | 88.5 (14.2) | .098 | 88.5 (17.0) | 88.7 (14.4) | .950 |
| Preoperative CKD, n (%) | 12 (11.0) | 1 (1.6) |
| 1 (1.7) | 1 (1.7) | 1.000 |
| Preoperative hemoglobin, g/L, mean (SD) | 116.3 (20.6) | 123.0 (17.2) |
| 122.7 (17.6) | 121.7 (15.8) | .750 |
Bold indicates statistical significance value (P < 0.05)
Abbreviations: ASA: American Society of Anesthesiologists; CKD: chronic kidney disease; IQR: inter‐quartile range; SD: standard deviation.
Perioperative outcomes for LPN and RPN after propensity score matching
| LPN (n = 58) | RPN (n = 58) |
| |
|---|---|---|---|
| Surgical approach (retroperitoneal), n (%) | 34 (58.6) | 38 (65.5) | .444 |
| Operating time, min, mean (SD) | 219.1 (33.0) | 198.8 (65.9) |
|
| Estimated blood loss, mL, median (IQR) | 200 (100‐300) | 160 (100‐212.5) | .405 |
| Warm ischemia time, min, mean (SD) | 24.2 (4.5) | 22.4 (3.6) |
|
| Transfusion, n (%) | 11 (19.0) | 5 (8.6) | .106 |
| Conversion, n (%) | 5 (8.6) | 2 (3.4) | .242 |
| To open surgery | 2 (3.4) | 0 | .496 |
| To radical surgery | 4 (6.9) | 2 (3.4) | .402 |
| Postoperative hospital stay, days, median (IQR) | 9 (7‐10.5) | 7.5 (6‐9) |
|
| Postoperative complications, n (%) | 17 (29.3) | 12 (20.7) | .284 |
| Low grade (Clavien‐Dindo I–II), n (%) | 13 (22.4) | 9 (15.5) | .343 |
| High grade (Clavien‐Dindo III–IV), n (%) | 4 (6.9) | 3 (5.2) | .697 |
| Pathologic stage | .701 | ||
| pT1b, n (%) | 39 (67.2) | 44 (75.9) | |
| pT2, n (%) | 2 (3.4) | 1 (1.7) | |
| pT3a, n (%) | 5 (8.6) | 4 (6.9) | |
| Fuhrman grade | .741 | ||
| Low (≤2), n (%) | 31 (53.4) | 34 (58.6) | |
| High (≥3), n (%) | 7 (12.1) | 5 (8.6) | |
| Not specified, n (%) | 8 (13.8) | 10 (17.2) | |
| Histologic subtype | .469 | ||
| Benign, n (%) | 12 (20.7) | 9 (15.5) | |
| Malignant, n (%) | 46 (79.3) | 49 (84.5) | |
| Positive surgical margin, n (%) | 1 (1.7) | 2 (3.4) | 1.000 |
| eGFR within postoperative 1 wk, mL/min, mean (SD) | 73.2 (18.0) | 73.9 (15.4) | .805 |
| eGFR decrease in baseline, mL/min, mean (SD) | −15.4 (3.4) | −14.8 (3.5) | .358 |
| Last follow‐up eGFR, mL/min, mean (SD) | 77.2 (21.1) | 80.8 (14.9) | .293 |
| eGFR decrease in baseline, mL/min, mean (SD) | −11.3 (13.0) | −7.9 (6.3) | .077 |
| De novo CKD at last follow‐up, n (%) | 11 (19.0) | 4 (6.9) | .053 |
Bold indicates statistical significance value (P < 0.05)
Abbreviations: CKD: chronic kidney disease; IQR: inter‐quartile range; SD: standard deviation.
Figure 1Kaplan‐Meier analyses for overall, cancer‐specific and progression‐free survivals according to the surgical type. A, Overall survivals of LPN and RPN before propensity score matching. B, Cancer‐specific survivals of LPN and RPN before propensity score matching. C, Progression‐free survivals of LPN and RPN before propensity score matching. D, Overall survivals of LPN and RPN after propensity score matching. E, Cancer‐specific survivals of LPN and RPN after propensity score matching. F, Progression‐free survivals of LPN and RPN after propensity score matching
Figure 2Kaplan‐Meier analyses for overall, cancer‐specific and progression‐free survivals of the LPN and RPN groups according to the surgical approaches. A, Overall survivals of TLPN and RLPN after propensity score matching. B, Cancer‐specific survivals of TLPN and RLPN after propensity score matching. C, Progression‐free survivals of TLPN and RLPN after propensity score matching. D, Overall survivals of TRPN and RRPN after propensity score matching. E, Cancer‐specific survivals of TRPN and RRPN after propensity score matching. F, Progression‐free survivals of TRPN and RRPN after propensity score matching. RLPN: retroperitoneal LPN; TLPN: transperitoneal LPN; RRPN: retroperitoneal RPN; TRPN: transperitoneal RPN